Printer Friendly

Browse Lung cancer, Small cell topic

Care and treatment subtopic

Articles

1-132 out of 132 article(s)
Title Author Type Date Words
United States : CHMP Issues Positive Opinion to Expand CYRAMZA (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Dec 16, 2019 504
United States : Data from Exploratory Analysis Show Mercks KEYTRUDA (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status. Dec 14, 2019 434
United States : Mercks KEYTRUDA (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy. Nov 30, 2019 311
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer. Nov 29, 2019 1489
Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer; POSEIDON included both non-squamous and squamous patients and a broad choice of standard chemotherapy ... Oct 29, 2019 1868
AstraZeneca (NYSE: AZN) - Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer -- 28/10/2019. Oct 29, 2019 337
United States : Lilly's CYRAMZA (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology. Oct 14, 2019 456
Switzerland : First-line treatment with Tecentrik monotherapy extends survival for certain patients with advanced non-small cell lung cancer compared to chemotherapy. Oct 14, 2019 223
Merck & Company, Inc. (NYSE:MRK) - Merck's KEYTRUDA[R] (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 -- 2/10/2019. Oct 7, 2019 540
Roche's Satralizumab Achieves Positive Phase III Results in NMOSD: Merck KGaA's tepotinib granted Breakthrough Designation in non-small cell lung cancer. Oct 1, 2019 1712
Bristol-Myers Squibb Shows Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Oct 1, 2019 149
AstraZeneca Data Shows Tagrisso as the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years. Oct 1, 2019 580
Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years. Sep 30, 2019 2054
United States : Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Financial report Sep 30, 2019 110
ASTRO: NSAIDs May Offer Benefit to Head & Neck Cancer Patients; Benefit not significant for aspirin use in patients with non-small cell lung cancer undergoing SBRT. Sep 23, 2019 295
United States : Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients. Financial report Sep 17, 2019 396
AstraZeneca (NYSE: AZN) - Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer -- 4/9/2019. Sep 11, 2019 457
Eli Lilly and Company UK (NYSE: LLY) - Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer -- 9/9/2019. Financial report Sep 11, 2019 806
Ipsen - Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE[R]) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer - 8/9/2019. Conference news Sep 11, 2019 619
Switzerland : Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer. Sep 7, 2019 277
European Commission approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer. Sep 6, 2019 1496
AstraZeneca announces approval for Tagrisso in China as first-line treatment for EGFR-mutated non-small cell lung cancer. Sep 5, 2019 276
AstraZeneca announces approval for Tagrisso in China as first-line treatment for EGFR-mutated non-small cell lung cancer. Sep 5, 2019 272
Chugai Pharmaceutical Co., Ltd. - Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer -- 22/8/2019. Aug 27, 2019 727
Switzerland : CHMP recommends EU approval of Roches Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. Jul 30, 2019 378
CHMP recommends EU approval of Roche's Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. Jul 26, 2019 1395
Sequencing Of Circulating Free Dna From Small Cell Lung Cancer Patients. Jul 19, 2019 101
United Kingdom : Imfinzi is the only immunotherapy to demonstrate overall survival at three years in unresectable Stage III non-small cell lung cancer. Jun 12, 2019 478
Sotio's DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer. Jun 4, 2019 255
AstraZeneca Touts Imfinzi is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer. Jun 4, 2019 768
Five-Year Survival Data for US Merck's Keytruda in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting. Jun 3, 2019 679
United States : European Commission Approves Lorviqua (Lorlatinib) for Certain Adult Patients With Previously-treated Alk-positive Advanced Non-small Cell Lung Cancer. May 11, 2019 567
Bristol-Myers Squibb Releases Long-Term Survival Results from Pooled Analyses of Opdivo in Previously-Treated Non-Small Cell Lung Cancer Patients. Apr 5, 2019 107
European Commission Approves US Merck's Keytruda (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer. Mar 15, 2019 497
Pfizer Receives Positive CHMP Opinion for Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer. Mar 4, 2019 444
Advaxis Enrolls First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer. Feb 19, 2019 413
European Medicines Agency Adopts Positive Opinion for US Merck's Keytruda in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC). Feb 4, 2019 430
United States : Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of. Report Dec 10, 2018 105
Roche PH launches immunotherapy for previously treated non-small cell lung cancer. Dec 6, 2018 577
European Commission Approves Alunbrig for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe. Nov 28, 2018 351
Roche (Philippines) Inc. launches immunotherapy for previously treated non-small cell lung cancer. Nov 26, 2018 610
United States : Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer. Nov 6, 2018 207
Switzerland : Roches Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer. Oct 25, 2018 633
Switzerland : Roches Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone. Oct 25, 2018 133
Genentech's Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone. Oct 24, 2018 183
Bristol-Myers Squibb Says Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer. Oct 12, 2018 696
Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy. Liu, Shuai; Chen, Peng; Liu, Yan-Wei; Gu, Xue-Nan; Qiu, Xiao-Guang; Li, Bo Report Oct 1, 2018 4742
Takeda Receives Positive CHMP Opinion Recommending Alunbrig (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib. Sep 24, 2018 1082
Prognostic analysis of surgical-pathologic N1 disease in non-small cell lung cancer: Single-center experience with 276 cases. Yazgan, Serkan; Ucvet, Ahmet; Gursoy, Soner; Samancilar, Ozgur; Guvenc, Ezgi Cimen Sep 1, 2018 3728
United Kingdom : Tagrisso approved in Japan for 1st-line treatment of EGFR-mutated non-small cell lung cancer. Aug 23, 2018 342
Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer. Dong, Jie; Wang, Xu; Yu, Yu; Yan, Xu; Cui, Jiu-Wei Report Aug 20, 2018 3710
Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression. Saxena, Ashish Report Jul 1, 2018 1764
United States : Mercks KEYTRUDA (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study. Report Jun 13, 2018 280
United States : Mercks KEYTRUDA (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study. Jun 13, 2018 374
Genentech's Tecentriq Plus Chemotherapy Decreases the Risk of Disease Worsening or Death for People with Advanced Squamous Non-Small Cell Lung Cancer in Phase III IMpower131 Study. Jun 7, 2018 282
Switzerland : Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer. Jun 5, 2018 282
United States : Mercks KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial. May 29, 2018 230
Clinically Significant Dysregulation of hsa-miR-30d-5p and hsa-let-7b Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer. Hosseini, Sayed Mostafa; Soltani, Bahram Mohammad; Tavallaei, Mahmoud; Mowla, Seyed Javad; Tafsiri, Apr 1, 2018 4541
AbbVie Will Not Seek Accelerated Approval of Rova-T for Third-Line Treatment of Certain Patients with Relapsed/Refractory Small Cell Lung Cancer. Mar 26, 2018 243
Japan : Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer. Feb 24, 2018 275
Japan : Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Feb 8, 2018 352
Japan : Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, TECENTRIQ Intravenous Infusion 1200mg for the Treatment of Unresectable, Advanced or Recurrent Non-small Cell Lung Cancer. Jan 20, 2018 370
Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C. Morris; Karim, Nagla Abdel Disease/Disorder overview Jan 1, 2018 3229
Comparative Evaluation of Mediastinal Lymph Nodes in Non-small Cell Lung Cancer with Computed Tomography, 99mTc-MIBI SPECT, and Video-Mediastinoscopy. Onal, Omer; Demir, Omer Faruk Clinical report Dec 1, 2017 3991
United Kingdom : AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan. Nov 28, 2017 115
Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. Tezel, Gaye Guler; Sener, Ebru; Aydin, Cisel; Onder, Sevgen Nov 1, 2017 3095
Bristol-Myers Squibb Study Shows Opdivo Combined with Yervoy Doubles ORR Compared to Opdivo Alone in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden. Oct 17, 2017 448
United States : Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032. Oct 17, 2017 469
United States : Thermo Fisher Scientific's Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from First Regional Health Plan. Oct 17, 2017 324
EMA accepts MAA for Imfinzi in locally-advanced unresectable non-small cell lung cancer. Oct 9, 2017 181
United States : Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Sep 11, 2017 409
Thermal Ablation in the Management of Adrenal Metastasis Originating from Non-small Cell Lung Cancer: A 5-year Single-center Experience. Botsa, Evanthia; Thanou, Ioanna; Papatheodoropoulou, Aspasia; Thanos, Loukas Report Sep 1, 2017 3228
United States : Imfinzi granted Breakthrough Therapy Designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer. Aug 2, 2017 371
EC approves first-line use of Novartis' Zykadia in ALK-positive advanced non-small cell lung cancer. Jun 29, 2017 231
Thermo Fisher receives US FDA premarket approval for its Oncomine Dx Target Test for non-small cell lung cancer detection. Jun 23, 2017 278
United States : Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003. Report Apr 4, 2017 353
Spectrum Pharmaceuticals Launches Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Mar 31, 2017 292
EC Approves US Merck's Keytruda for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer When Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations. Feb 1, 2017 332
Merck submits sBLA for KEYTRUDA with the US FDA for the treatment of patients with advanced non-small cell lung cancer. Jan 11, 2017 326
Merck submits sBLA for KEYTRUDA with the US FDA for the treatment of patients with advanced non-small cell lung cancer. Jan 11, 2017 322
Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. Huang, Bao-Tian; Zhang, Wu-Zhe; Wu, Li-Li; Lin, Pei-Xian; Lu, Jia-Yang Report Jan 1, 2017 5838
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. Jiang, Wei; Zhang, Wenjue; Wu, Lihong; Liu, Lipin; Men, Yu; Wang, Jingbo; Liang, Jun; Hui, Zhouguang Report Jan 1, 2017 5433
Altered Brain Functional Connectivity in Small-Cell Lung Cancer Patients after Chemotherapy Treatment: A Resting-State fMRI Study. Bromis, Konstantinos; Gkiatis, Kostakis; Karanasiou, Irene; Matsopoulos, George; Karavasilis, Eustra Report Jan 1, 2017 6303
Merck receives positive recommendation for KEYTRUDA for treating metastatic non-small cell lung cancer in adults. Dec 19, 2016 311
Merck receives positive recommendation for KEYTRUDA for treating metastatic non-small cell lung cancer in adults. Dec 19, 2016 307
United States : Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer. Oct 10, 2016 146
Japan : Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer. Oct 7, 2016 463
Pfizer passes EC approval for XALKORI (crizotinib) for the treatment of ROS1-positive advanced non-small cell lung cancer. Sep 1, 2016 266
Pfizer passes EC approval for XALKORI (crizotinib) for the treatment of ROS1-positive advanced non-small cell lung cancer. Sep 1, 2016 262
United States : XALKORI (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer. Sep 1, 2016 437
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 256
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 252
United States : Mercks KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1. Aug 3, 2016 270
Spain : PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer. Report Aug 3, 2016 280
Merck passes conditional approval for KEYTRUDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in Canada. Apr 21, 2016 360
Merck passes conditional approval for KEYTRUDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in Canada. Apr 21, 2016 356
Clovis Oncology's NDA for Rociletinib to be reviewed by the US FDA for non-small cell lung cancer. Apr 13, 2016 200
Clovis Oncology's NDA for Rociletinib to be reviewed by the US FDA for non-small cell lung cancer. Apr 13, 2016 196
United States : Tagrisso (osimertinib) approved in Japan for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Mar 30, 2016 496
United States : XALKORI Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer. Mar 14, 2016 514
United States : FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. Mar 12, 2016 618
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Kerr, Keith M.; Nicolson, Marianne C. Mar 1, 2016 5316
United Kingdom : TAGRISSO (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Feb 4, 2016 659
Delaying chemotherapy in the treatment of stage IV non-small cell lung cancer does not adversely affect survival outcome. Mozayen, Mohammad; Alsharedi, Mohamed; Mehmi, Inderjit; Gress, Todd; Tirona, Maria Tria Report Jan 1, 2016 2424
United States : TAGRISSO (osimertinib) receives positive CHMP opinion for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Dec 19, 2015 553
Pfizer passes approval in Europe to expand use of XALKORI to first-line treatment of adults with ALK positive advanced non-small cell lung cancer. Nov 25, 2015 285
Pfizer passes approval in Europe to expand use of XALKORI to first-line treatment of adults with ALK positive advanced non-small cell lung cancer. Nov 25, 2015 281
Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancer. Report Oct 31, 2015 3078
Diplomat to introduce IRESSA as a first-line treatment for selected patients with metastatic non-small cell lung cancer. Aug 11, 2015 261
Diplomat to introduce IRESSA as a first-line treatment for selected patients with metastatic non-small cell lung cancer. Aug 11, 2015 257
AmoyDx, Supplier of MoBiTec, Germany, Introduces System for Extraction of Circulating DNA from NSCLC (Non-Small Cell Lung Cancer) Patients. Jun 26, 2015 383
United States : FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer. Dec 13, 2014 457
Germany : New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF (afatinib) compared to chemoth. Nov 10, 2014 430
United Kingdom : Tafinlar receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation. Jan 14, 2014 298
Conjunctival metastasis as an initial sign of small cell lung cancer. Sahin, Afsun; Yildirim, Nilgun; Sahin, Deniz Goren; Basmak, Hikmet; Acikalin, Mustafa Case study Jan 1, 2014 908
Axelar reports final results from Phase II study with AXL1717 in patients with non-small cell lung cancer. Clinical report Dec 30, 2013 151
Axelar reports final results from Phase II study with AXL1717 in patients with non-small cell lung cancer. Clinical report Dec 30, 2013 147
Japan : New Drug Application Filed for ALK Inhibitor Alectinib Hydrochloride for the Treatment of ALK Fusion Gene Positive Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer. Oct 9, 2013 415
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Ruschoff, Josef; Kerr, Keith M.; Grote, Hans J.; Middel, Peter; von Heydebreck, Anja; Alves, Venanci Report Sep 1, 2013 5302
Switzerland : Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer. Jun 4, 2013 434
i"?OncoMed Pharmaceuticals starts Phase 1b/2 trial of OMP-59R5 (Anti-Notch2/3) in small cell lung cancer patients. May 16, 2013 141
i"?OncoMed Pharmaceuticals starts Phase 1b/2 trial of OMP-59R5 (Anti-Notch2/3) in small cell lung cancer patients. May 16, 2013 137
i"? Axelar's AXL-003 indicates efficacy in second line treatment of non-small cell lung cancer patients. Apr 3, 2013 130
i"? Axelar's AXL-003 indicates efficacy in second line treatment of non-small cell lung cancer patients. Apr 3, 2013 126
Switzerland : Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer. Mar 15, 2013 416
Targeted therapy successful against most common form of non-small cell lung cancer. Mar 1, 2013 116
Case report: metastatic small-cell lung carcinoma of the external auditory canal. Hain, Moshe; Feldberg, Edit; Halperin, Doron Case study Nov 1, 2012 1212
The case of confounded confusion. Eisenberg, Seth Case study Oct 1, 2011 341
Cranial irradiation slows lung cancer spread. Clinical report Sep 22, 2007 322
Brain irradiation boosts survival in SCLS patients. Lovinger, Sarah Pressman Clinical report Jul 1, 2007 374
Reversing drug resistance in patients with lung cancer may save lives. McBride, Deborah Brief article Mar 1, 2007 203
Vitamin D plus summer surgery boosted lung cancer survival. Finn, Robert Jun 15, 2005 430

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters